Halozyme Therapeutics (NASDAQ:HALO) Downgraded by JPMorgan Chase & Co.
JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) from an overweight rating to a neutral rating in a research note published on Thursday morning, Marketbeat Ratings reports. The firm currently has $57.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $52.00. HALO has been […]
22 Sep 07:49 · The Markets Daily